close

Enter

Log in using OpenID

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Growth Analysis to 2026

embed
Increasing drug approvals by regulatory authorities is expected to boost the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.
Chronic Inflammatory Demyelinating Polyneuropathy
Treatment Market Size, Share, Trend, Outlook,
Future Growth Analysis And Synthesis 2018 - 2026
Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is a rare neurological disorder which causes
paralysis (impairment of sensory function in limbs). It occurs due to the inflammation of nerve roots,
peripheral nerves, and destruction of the fatty protective covering (myelin sheath) over the nerves. It
slows down the transmission of nerve signals, thus leading to destruction of nerve fibers. It can be
treated with corticosteroids or in combination with an immunosuppressant, plasma exchange, and
intravenous immunoglobulin therapy.
Request a Sample of This Research Report: https://www.coherentmarketinsights.com/insight/requestsample/2609
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Drivers
Increasing drug approvals by regulatory authorities is expected to boost the global chronic inflammatory
demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in March 2017, CSL
Behring received U.S. Food and Drug Administration (FDA) approval for Privigen, an immunoglobulin
therapy for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. 207
patients were treated with Privigen for 13 weeks and 73% out of these 207 patients responded to it in
clinical trials. Furthermore, in March 2018, CSL Behring received U.S. FDA approval for Hizentra, which
is a type of subcutaneous immunoglobulin therapy that prevents relapsing neuromuscular disability. It
offers a convenient treatment type, in which patients can infuse themselves. The approval was based on
the phase III results of the clinical trial. These factors are expected to propel the global chronic
inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Regional Analysis
North America is expected to hold a dominant position in the global chronic inflammatory demyelinating
polyneuropathy (CIDP) treatment market. Factors such as initiatives from governments and other
organizations are expected to have an influence on the global chronic inflammatory demyelinating
polyneuropathy (CIDP) treatment market growth. For instance, in April 2019, Guillain-Barre syndrome &
Chronic Inflammatory Demyelinating Polyneuropathy (GBS | CIDP) international foundation announced
that it is going to celebrate May as GBS | CIDP awareness month. They plan to create awareness about
the foundation’s legislative initiatives for CIDP patients through social media and campaigns. The
initiative is for creating a bill which includes the establishment of the Medicare Part B Home Infusion
Demonstration Project, and increase in funds for treatment of CIDP patients. These factors are expected
to have a positive impact on the global chronic inflammatory demyelinating polyneuropathy (CIDP)
treatment market growth.
Report includes chapters which deeply display the following deliverable about industry :
• Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Research Objective and
Assumption
• Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Purview - Report
Description, Executive Summary, and Coherent Opportunity Map (COM)
• Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Dynamics, Regulations,
and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and
Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST
Analysis
• Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market, By Regions
• Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Competition by
Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base
Distribution, Sales Area and Product Type.
• Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Manufacturers Profiles/
Analysis including Company Basic Information, Manufacturing Base and Its Competitors.
• Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Manufacturing Cost
Analysis including Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Forecast including
Production, Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Key Players
Some of the major players operating in the global chronic inflammatory demyelinating polyneuropathy
(CIDP) treatment market include CSL Behring, Kedrion S.p.A., Takeda Pharmaceutical Co. Ltd., Shire
Plc., GeNeuro SA ,Baxter International Inc., Octapharma AG and Grifols S.A., Teijin Pharma Ltd. and
Nihon Pharmaceutical Co. Ltd.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment Market Taxonomy
The global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market is segmented by
treatment type, distribution channel and regions.
By Treatment Type
- Intravenous immunoglobulin therapy
•
Privigen
•
Hizentra
•
Gamunex-C
•
Tegeline
•
Others
- Corticosteroids
- Others
By Distribution Channel
•
Hospital pharmacies
•
Retail pharmacies
•
Online pharmacies
Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoinginsight/chronic-inflammatory-demyelinating-polyneuropathy-cidp-treatment-market-2609
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Poul Master
Poul Master247   documents Email
1/--pages
Report inappropriate content